α-FLT3-A192

α-FLT3-A192 is a recombinant fusion protein nanoparticle designed to target the FMS-like tyrosine kinase 3 (FLT3) receptor, which is frequently mutated or overexpressed in acute myeloid leukemia (AML). The molecule consists of a single-chain variable fragment (scFv) antibody, derived from the IMC-EB10 sequence, fused to an elastin-like polypeptide (ELP) called A192. This fusion allows the protein to assemble into stable, multi-valent, rod-like nanoparticles (nanoworms) that exhibit an extended pharmacokinetic half-life compared to free scFvs. Mechanistically, α-FLT3-A192 binds to domain 4 of the FLT3 receptor, inhibiting downstream proliferative signaling pathways such as STAT5 and ERK, thereby inducing apoptosis in FLT3-ITD+ leukemic cells. It was developed by researchers at the University of Southern California as a potential therapeutic to overcome the limitations of small-molecule tyrosine kinase inhibitors and traditional monoclonal antibodies in AML.

Other names

anti-FLT3-A192anti-FLT-3-A192anti-FLT 3-A192α-FLT3-ELP fusion proteinanti-FLT3 scFv-ELP nanoparticleanti-FLT-3 scFv-ELP nanoparticleanti-FLT 3 scFv-ELP nanoparticle